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Abstract
Background: Ecteinascidin 743 (Et 743) is a potent antitumor
marine alkaloid currently undergoing phase II clinical trials. The
synthetic analog phthalascidin (Pt 650), a designed structural
analog of Et 743 displays in vitro potency comparable to Et 743.
In this study, we used a panel of 36 human cancer cell lines, flow
cytometry and oligonucleotide microarrays to analyze further
these two compounds in a parallel fashion with regard to both
antitumor activity (phenotype) and gene expression (genotype)
bases.
Results : The cancer panel experiment established that activity
patterns of Et 743 and Pt 650 were essentially the same with their
IC50 values ranging from pM to low nM. By means of flow
cytometric cell cycle analysis using HCT116 cells, they were shown
to disrupt S phase progression after a 12-h treatment at 2.0 nM,
eventually resulting in the late S and G2/M accumulation at
the 24-h time point. Array-based gene expression monitoring
also demonstrated that the Et 743 and Pt 650 profiles were
highly similar in two distinct cancer cell lines, HCT116 colon and
MDA-MB-435 breast. Characteristic changes were observed
in subsets of genes involved in DNA damage response, transcrip-
tion and signal transduction. In HCT116 carrying the wild-
type p53 tumor suppressor gene, the up-regulation of several
p53-responsive genes was evident. Furthermore, a subset of
genes encoding DNA-binding proteins to specific promoter
regions (e.g. the CCAAT box) was down-regulated in both cell
lines, suggesting one potential mode of action of this series of
antitumor agents.
Conclusion: A combination of gene expression analysis using
oligonucleotide microarrays and flow cytometry confirms an
earlier finding that Et 743 and Pt 650 have remarkably similar
biological activities. ß 2001 Elsevier Science Ltd. All rights re-
served.
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1. Introduction
Ecteinascidin 743 (Et 743) is an exceedingly potent and
rare marine-derived antitumor agent isolated from the tu-
nicate Ecteinascidia turbinate [1]. Because of its remarkable
preclinical activity against various cancer cell lines in vitro
and against several human tumor xenografts in vivo, Et
743 has entered into clinical trials and has progressed to
phase II studies in Europe and the United States [2^5]. To
compensate for the scarcity of availability from the natu-
ral source, Et 743 has recently been synthesized by a pro-
cess that is being applied for the supply of clinical samples
[6]. By using similar synthetic approaches, a number of
analogs have also been prepared for biological evaluation,
resulting in the discovery of phthalascidin (Pt 650) that is
comparable to Et 743 with respect to its in vitro antipro-
liferative potency (Fig. 1) [7^9].
Although many objective responses have been observed
in clinical tumors including sarcoma, melanoma and
breast carcinoma, the precise mechanism of action of Et
743 has yet to be fully understood. The compound alkyl-
ates the N2 position of guanine in the minor groove of
duplex DNA with some sequence speci¢city for 5P-AGC,
5P-CGG, 5P-GGC, 5P-TGC, etc. [10,11], and thus bends
DNA toward the major groove [12]. Poisoning of DNA
topoisomerase I (topo I) was also reported by Takebaya-
shi et al. [13] and by our group [7] independently. How-
ever, we clearly mentioned in the paper that the topo I
inhibition seemed to be only an auxiliary e¡ect incidental
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to the primary mechanism of action of Et 743 and Pt 650.
This statement was based on the experimental facts that
very high drug concentrations (WM range) were required
for optimum DNA topo I cross-linking and that campto-
thecin (another topo I inhibitor)-resistant murine leukemia
cells completely retained sensitivity to these two com-
pounds. Consistent with our results, a more recent paper
by Erba et al. described that pharmacologically reasonable
concentrations of Et 743 (nM range) yielded neither DNA
strand break nor DNA^protein cross-linking in sensitive
cells [14]. Furthermore, Takebayashi et al. [15] and Damia
et al. [16] reported that P388 CPT45 murine leukemia cells
and CY2278 yeast cells, not expressing the topo I gene in
both, were invariably sensitive to Et 743 while showing
resistance to camptothecin. Therefore, all these ¢ndings
indicate that topo I is not the primary target for the anti-
proliferative activity of Et 743.
Apart from the topo I poisoning, DNA binding of the
CCAAT box transcription factor NF-Y was shown to be
impaired by Et 743 in a cell-free in vitro experiment albeit
at concentrations (10 and 30 WM) much higher than are
su⁄cient for potent cytotoxicity [17]. Employing cell-based
assay systems, two parallel studies by Jin et al. [18] and
Minuzzo et al. [19] further revealed that Et 743 interfered
with induced transcriptional activation in a CCAAT-de-
pendent manner at physiologically relevant nM concentra-
tions. According to their reports, the activation of the
MDR1 and HSP70 promoters, both of which contain
the CCAAT box, were signi¢cantly repressed by Et 743
with minimal inhibitory e¡ects on constitutive expression
of the MDR1 and HSP70 genes. These data suggest that
Et 743 targets induce NF-Y-mediated transcription, dis-
tinct from other DNA-interacting anticancer drugs.
Based on the important observations described above,
we decided to utilize oligonucleotide microarrays for char-
acterizing transcriptional e¡ects of Et 743 and Pt 650.
Fig. 1. Structures of ecteinascidin 743 (Et 743) and phthalascidin (Pt
650).
Fig. 2. IC50 mean graphs and COMPARE analysis. Based on the MTT assay data, the IC50 value of each test drug was determined by the least-squares
method. The arithmetic mean of the log IC50 values for all 36 cell lines was then calculated for each compound. The delta value of each cell line, de-
¢ned as the di¡erence between the logarithm of the cell line IC50 and the mean, was also calculated. The mean graph was constructed by projecting
bars to the right or left of the mean, depending on whether cell sensitivity to a compound was more or less than average. All graphs were illustrated
with the length of a bar proportional to the delta value. The Pearson product moment correlation coe⁄cients for each set of delta value pairs between
two test compounds were determined by using a statistical program. The correlation data between Et 743 and other drugs are presented here.
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Activity-based comparative pro¢ling was also carried out
with a panel of 36 human cancer cell lines and £ow cyto-
metry to determine appropriate experimental conditions
(i.e. drug concentration and exposure time) for microarray
analysis. Transcriptional pro¢ling presented herein ap-
pears to be a powerful tool in examining the mechanistic
basis of this class of transcription-targeting agents.
2. Results and discussion
2.1. Mean graph-based COMPARE analysis
By using a panel of 36 human cancer cell lines, the
antiproliferative activities of Et 743 and Pt 650 were eval-
uated and compared with those of several well-known
anticancer agents, i.e. camptothecin (topo I inhibitor),
adriamycin (DNA-intercalating topo II inhibitor), cispla-
tin (CDDP, DNA-alkylating agent), mitomycin C (MMC,
DNA-alkylating agent) and taxol (microtubule-stabilizing
antimitotic agent). The results of 3-day MTT assays [20]
are presented in Fig. 2 as mean graphs for the test drugs.
Et 743 and Pt 650 demonstrated prominent growth inhi-
bition potencies in the range of pM to low nM. The means
of the logarithm of the IC50 values for these two were
calculated at 39.45 and 39.60, respectively. Obviously,
both compounds were orders of magnitude more potent
than the other anticancer agents. Breast cancer cell lines
tended, on average, to be more sensitive than colon, lung,
stomach and pancreas to Et 743 and Pt 650. Pt 650 has
been assessed as NSC701549 by the Developmental Ther-
apeutic Program (DTP) of the NCI, with comparable re-
sults (data not shown).
The NCI has developed the COMPARE program with
a set of 60 human cancer cell (NCI60) lines, in which mean
graph ‘¢ngerprints’ are used to characterize the activity
pro¢les of test drugs [21]. It has been shown that agents
operating by a similar mechanism of action produce com-
parable antitumor spectra on the mean graph basis. Thus,
the correlation coe⁄cients between Et 743 and the other
six compounds were determined by using the sets of delta
values from their mean graphs. As expected, a high corre-
lation was observed between Et 743 and Pt 650 (r = 0.90).
In contrast, all the correlation coe⁄cients between Et 743
and each of the other drugs were less than 0.5. These
results suggest that Et 743 and Pt 650 share a primary
mechanism di¡erent from those utilized by the well-de-
¢ned anticancer agents, and that only simple DNA alkyl-
ation and topo I inhibition cannot account for their activ-
ity pro¢les.
The tumor suppressor protein p53 plays a central role in
cell cycle arrest, DNA repair and cellular apoptosis in
response to DNA damage [22]. It has been reported that
the mutant p53 cell lines tend to be less sensitive than the
wild-type p53 lines to a wide variety of DNA-alkylating
agents, DNA/RNA antimetabolites, and topo I and II
inhibitors [23]. Although the 36 human cancer cell lines
used in this study include both cell types (e.g. HCT116 and
NCI-H460 keep wild-type p53, while SW620, COLO205,
HT-29, MDA-MB-231 and MDA-MB-435 contain mu-
tated p53; [23]), the antiproliferative activities of Et 743
and Pt 650 appear to be unrelated to the p53 status. In a
recent paper, Erba et al. also stated this point more evi-
dently based on the observation that Et 743 exhibited very
much the same cytotoxicity against isogenic cellular sys-
tems with di¡erent p53 expression [14]. It is an obvious
merit for this series of antitumor agents because p53 is
known to be altered in clinical tumors with a high fre-
quency.
2.2. Time-course pro¢les of the growth inhibition of
Et 743 and Pt 650
From the results of 3-day MTT assays, the IC50 values
of Et 743 and Pt 650 for HCT116 cells were estimated to
be 0.32 and 0.23 nM, respectively. Thus, they were further
tested at 2.0 nM to examine time-course pro¢les of their
antiproliferative e¡ects on the same cell line. As shown in
Fig. 3, no signi¢cant di¡erences in cell growth were found
at the 12-h time point among cells untreated (control), Et
743-treated and Pt 650-treated. After 24 h of treatment,
growth inhibition was evident for both compounds. At
time points of 24 and 48 h, cellular apoptosis was detect-
able in both Et 743- and Pt 650-treated cells by nuclear
staining with the Hoechst 33342 dye (data not shown).
2.3. Cell cycle analysis with Et 743 and Pt 650
By using £ow cytometry, the e¡ects of Et 743 and Pt
Fig. 3. Time-course pro¢les of the drug e¡ect on HCT116 cell growth.
The experiment was carried out in triplicate with each of Et 743 and
Pt 650 at 2.0 nM. The initial cell number was 1.0U106 cells per well
(2.0 ml). The relative cell numbers at time points of 0, 12, 24 and 48 h
are plotted in a semi-logarithmic graph. The plotted values represent the
means of three independent data.
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650 on cell cycle progression were investigated. HCT116
cells were exposed to 2.0 nM of each compound for 12 or
24 h. As DNA histograms in Fig. 4 show, cell cycle per-
turbation in the S phase was evident for both compounds
at the 12-h time point leading after 24 h to a conspicuous
accumulation of the cells in the late S and G2/M phases.
These observations are consistent with those presented by
Erba et al. using 20 and 80 nM of Et 743 for SW620 and
Fig. 4. Flow cytometric cell cycle analysis. The e¡ects of Et 743 and Pt 650 on cell cycle progression were examined according to the procedure de-
scribed in Section 4. HCT116 cells were treated with 2.0 nM of each compound for 12 or 24 h. DNA histograms from drug-treated and untreated cells
are shown here.
Fig. 5. Average di¡erence scatter correlation graphs. The transcription pro¢les of Et 743 and Pt 650 were compared in two cancer cell lines HCT116 co-
lon and MDA-MB-435 breast. Average di¡erence change values for all gene probes were calculated as the means of two independent values from dupli-
cate array experiments. The means more than 50 for both compounds before antibody ampli¢cation are plotted in scatter correlation graphs for
HCT116 and MDA-MB-435. These were also used after eliminating the data sets of the genes absent (designated A) in both control and drug-treated
cells, yielding the Pearson product moment correlation coe⁄cients between Et 743 and Pt 650.
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LoVo cells, respectively [14] and by Takebayashi et al. [15]
using 10 nM of Et 743 for HCT116 cells.
2.4. Comparison of Et 743 and Pt 650 pro¢les on the gene
expression basis
In order to pro¢le comparatively Et 743 and Pt 650, we
investigated mRNA levels for more than 5000 di¡erent
genes in sensitive cancer cell lines by using A¡ymetrix
HuGeneFL oligonucleotide arrays. Based on the results
of the phenotypic examinations described above, we ¢xed
the experimental parameters for microarray analysis as
follows: (i) cancer cell lines, HCT116 colon with wild-
type p53 and MDA-MB-435 breast with mutated p53
and (ii) drug concentration and exposure time, 2.0 nM
and 12 h for both compounds. The choice of these two
cell lines was guided by their di¡erences with respect to
p53 status. The gene product of p53 is known to act as a
transcription factor induced by DNA damage, and thus its
status, wild-type or mutated, can be in£uential in tran-
scription pro¢les of DNA-interacting agents like Et 743
and Pt 650. In fact, Et 743 treatment at 20 nM for 6 h
was found to elevate the levels of the p53 protein in LoVo
cells carrying wild-type p53, but not in SW620 cells pos-
sessing mutated p53 [14]. The conditions for drug treat-
ment (2.0 nM drug for 12 h) were chosen to avoid the
complications of terminal expression changes resulting
from apoptosis and to detect primarily the early e¡ects
of the test drugs on transcription.
Illustrated in Fig. 5 are average di¡erence scatter corre-
lation graphs for both HCT116 and MDA-MB-435 cell
lines, facilitating the comparison of the Et 743 and Pt
650 pro¢les. After eliminating data points that were unre-
liable due to low signal intensity or high background,
these graphs were prepared by using the GeneChip soft-
ware (A¡ymetrix). For each gene, the mRNA expression
level based on the average di¡erence change value in Et
743 treatment is given on the x-axis and the level of the
same gene in Pt 650 treatment is plotted on the y-axis.
Obviously, the Et 743 and Pt 650 pro¢les are highly sim-
ilar in both cell lines. The Pearson product moment cor-
relation coe⁄cients between these two data sets were cal-
culated at 0.993 utilizing 2829 gene probes in HCT116 and
at 0.986 utilizing 2786 gene probes in MDA-MB-435. The
probe selection criteria for the statistical calculation are
described in the legend to Fig. 5.
Shown in Fig. 6 are Venn diagrams representing the
number of genes that changed expression levels at least
two-fold in each of the Et 743 and Pt 650 data sets. The
criteria for the gene selection are described in the Fig. 6
legend. Table 1 provides a list of the up- and down-regu-
lated genes by drug treatment. Some important points in
the comparison of the Et 743 and Pt 650 pro¢les are sum-
marized below. First, the down-regulation of transcripts is
predominant over the up-regulation in both HCT116 and
MDA-MB-435. This observation appears to have some
relation to those in recent reports arguing that Et 743
exerts negative e¡ects on activated transcription not via
widespread Pol II inhibition but via functional interference
in some speci¢c gene promoters like the CCAAT box
[18,19]. Second, in the data set for HCT116, there is quite
signi¢cant overlap between down-regulated genes in Et
743- and Pt 650-treated cells and also between up-regu-
lated genes in Et 743- and Pt 650-treated ones. In contrast,
Fig. 6. Venn diagrams comparing sets of up- and down-regulated genes. In HCT116 colon and MDA-MB-435 breast cancer cells, induced or repressed
genes with each of Et 743 and Pt 650 were determined based on the following criteria of the A¡ymetrix software algorithm: (i) fold change, v 2.0 or
932.0; (ii) di¡erential call, I (increase) or D (decrease); (iii) absence call, genes except those displaying A (absent) in both control and drug-treated
cells ; (iv) genes satisfying all of (i)^(iii) in the data set either before or after antibody ampli¢cation; and (v) genes satisfying all of (i)^(iv) in both data
sets taken in duplicate.
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Table 1
Gene expression changes caused by Et 743 and Pt 650
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there is no overlap between down-regulated genes and up-
regulated ones with either Et 743 or Pt 650 treatment.
These correspond well to the correlation data based on
the average di¡erence scatter plot. Third, there is also
signi¢cant overlap between down-regulated genes in
HCT116 and MDA-MB-435. Et 743 and Pt 650 repressed
in common at least two-fold the expression of 57 and 92
genes for HCT116 and MDA-MB-435, respectively. Of
these, 42 genes are shared by both cell lines. Additionally,
10 of the 50 ( = 92342) genes repressed only in MDA-MB-
435 and four of the 15 ( = 57342) genes repressed only in
HCT116 were down-regulated in the other cell line by
either Et 743 or Pt 650 (data not shown). The comparable
transcriptional repression in both cell lines, derived from
completely unrelated clinical specimens, indicates the pres-
ence of a universal mechanistic basis for both compounds.
Of the total 15 up-regulated genes, however, only one gene
(p21/waf1/cip1) is common for HCT116 and MDA-MB-
435, suggesting that the induction of the genes be mainly
caused by independent mechanisms in these two cell lines.
As mentioned below, most of the genes induced in
HCT116 have been actually reported to be responsive to
functional p53, which is defective in MDA-MB-435. Tak-
en altogether, the gene expression-based pro¢ling, along
with the antitumor activity-based pro¢ling, strongly sug-
gests that Et 743 and Pt 650 operate by the same mode of
action potentially linked to speci¢c transcriptional repres-
sion.
2.5. Gene expression changes caused by Et 743 and Pt 650
The results summarized in Table 1 disclose that Et 743
and Pt 650 a¡ect the expression of a variety of genes,
including subsets of genes involved in DNA damage re-
sponse, transcription and signal transduction. It is impres-
sive that only 2.0 nM of each compound, a pharmacolog-
ically relevant and also physiologically achievable
concentration, can exert such signi¢cant e¡ects on the
transcription of whole cells. Both compounds have been
shown to be capable of interacting covalently, but revers-
ibly, with duplex DNA. The present study further revealed
that they markedly disrupted S phase progression in
HCT116 cells after 12 h of treatment. Consistent with
these phenotypic observations, the transcript levels of
brain and reproductive organ-expressed protein (BRE)
and DNA polymerase K-subunit were decreased in both
cell lines. It has been found that the expression of the BRE
gene is repressed in response to DNA damage [24]. More-
over, six of the nine genes up-regulated in HCT116 (see
Table 1, groups (D), (E) and (F)), GADD45, p21/waf1/
cip1, BTG2, a TGF-L superfamily member, RGS2/G0S8
and Fas/Apo-1, have been reported to be p53-regulated
genes induced in an early or intermediate response to
p53 activation [25]. Of these, only p21/waf1/cip1 was in-
duced in MDA-MB-435-containing mutated p53. Thus,
DNA damage caused by Et 743 and Pt 650 appears to
activate p53 regulatory pathways in cells with functional
Table 1 (Continued)
Up- and down-regulated genes were selected based on the same criteria as described in the legend to Fig. 6. The genes are listed according to the cate-
gories of the Fig. 6 Venn diagrams. Fold change values were calculated as the means of two independent values from duplicate array experiments. The
data after antibody ampli¢cation were generally used for the calculation. Only in case non-linear saturated ampli¢cation was evident by comparing
changes in average di¡erence values for some genes with those for control probes, their fold change values were determined employing the data before
antibody ampli¢cation.
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p53. However, it should be stated that the p53-dependent
transcriptional changes are not the primary mechanistic
basis for this class of antitumor agents because HCT116
and MDA-MB-435 cells were shown to be equally sensi-
tive to each compound in our cell-based assays. Although
cell cycle perturbation was evident in HCT116 after 12 h
of treatment, changes in the expression levels of cell cycle-
regulatory genes were generally inconspicuous at this time
point except for some relevant genes such as DNA poly-
merase K-subunit and p21/waf1/cip1.
Characteristic down-regulation was observed in a subset
of genes encoding DNA-binding proteins to speci¢c pro-
moter regions (see Table 1, group (G)). It is of particular
interest that all of their binding motifs contain DNA trip-
lets with a central guanine on either the template or anti-
sense strand. They are certainly Et 743-targeted (also
probably Pt 650-targeted) sequences. For instance, the
CCAAT sequence holds a TGG site on the complementa-
ry strand, which has been shown to be one of the preferred
sequences for Et 743 alkylation [10]. It is intriguing that
the gene products binding to the drug-targeted DNA se-
quences were repressed in the mRNA expression by drug
treatment. As mentioned above, Et 743 has been shown to
have a speci¢c negative e¡ect on transcriptional activation
by targeting the CCAAT box transcription factor NF-Y.
It has been also proposed that the Sp1-dependent tran-
scription requiring the GC box might be another potential
target for Et 743 action [18,19,26]. With relation to
these reports, the present study disclosed that the
mRNA levels of NF-Y subunit C (CBF-C/NF-YC) and
GC box-binding protein BTEB were decreased in both
Et 743- and Pt 650-treated MDA-MB-435 cells. Further-
more, transcriptional repression of CCAAT displacement
protein (CDP/cut) and ATF6, both of which are func-
tionally linked to the CCAAT box, was prominent in
both HCT116 and MDA-MB-435. CDP/cut has properties
of a potent transcriptional repressor associated with a
corepressor complex through interactions with histone
deacetylases [27]. This protein has also been found to be
within a transcriptional activating complex(es) through
interactions with histone acetyltransferase coactivators
CBP and PCAF [28]. ATF6 has been implicated in the
endoplasmic reticulum stress response pathway as an acti-
vator of stress-induced transcription with synergistic inter-
actions with NF-Y and YY1 [29]. A recent paper showed
that ATF6 could bind to CCACG only when CCAAT
exactly 9 bp upstream of CCACG was bound to NF-Y
[30].
The profound transcriptional repression of these genes
implies a unique mechanism of Et 743 and Pt 650 in their
interaction with DNA. It is unlikely that 2.0 nM of each
compound can completely eject NY-F from the high-a⁄n-
ity CCAAT box. This consideration is in accord with the
previous observations by Bonfanti et al. [17] that inhibi-
tion of NF-Y by Et 743 in vitro required much higher
drug concentrations (WM range) and that nuclear extracts
from cells treated with Et 743 retained normal NF-Y com-
plex formation. Et 743 has a tetrahydroisoquinoline sub-
unit (subunit C) in its structure, which appears to protrude
from the minor groove when the drug is bound to duplex
DNA [11]. Pt 650 possesses a phthalimide moiety at the
same position. Our previous structure^activity relationship
studies clari¢ed that the part of the subunit C was cru-
cially important for the exceedingly potent antitumor ac-
tivity of this series [7,8]. Depending on the structure of this
part, both compounds may a¡ect the ¢ne architecture
around some speci¢c promoter regions like the CCAAT
box, resulting in signi¢cant alterations in DNA^protein
and/or protein^protein interactions relevant to transcrip-
tional control. Given that distorted DNA structure causes
malfunctioning of some important proteins nearby DNA,
the down-regulation of their mRNA expression might be a
reasonable cellular response based on putative feedback
regulatory mechanisms. In this regard, one can note the
repression of not only the genes listed in group (G) but
also genes encoding coactivator 100-kDa subunit, core-
pressor SMRT, chromatin-associated proteins HMGIC
and SWI/SNF 155-kDa subunit, and DNA repair proteins
MGMT, XRCC4 and BRCA1. The negative e¡ects on
these DNA repair genes raise the possibility that Et 743
and Pt 650 are also in£uential in the complex formation of
DNA and repair proteins, relating to a recent ¢nding that
Et 743 activity is decreased in nucleotide excision repair-
de¢cient cell lines [16].
Another possible explanation for the characteristic
down-regulation is that Et 743 and Pt 650 may prevent
speci¢cally activated transcription in these cancer cells. In
fact, Et 743 has been shown to interfere with the activa-
tion of the MDR1 and HSP70 promoters without a¡ecting
the constitutive expression of the corresponding genes
[18,19]. Although we examined drug e¡ects on the consti-
tutive transcription of more than 5000 endogenous genes,
there might be some highly activated genes in the tran-
scription levels under cancerous conditions. With relation
to this speculation, Et 743 and Pt 650 down-regulated the
expression of a subset of signal transduction genes encod-
ing kinases, phosphatases and G protein signaling mole-
cules, many of which serve as positive mediators for cell
proliferation. The possibility that both compounds can
exert negative e¡ects on the promoter activity for these
genes is not excluded. Further extensive promoter analyses
for the genes listed here may a¡ord a clue for a valid
conclusion(s).
3. Signi¢cance
Herein described is antitumor activity- and gene expres-
sion-based pro¢ling of Et 743 and Pt 650, demonstrating
an intelligible example for integrated studies on phenotype
and genotype analyses. This is the ¢rst report to reveal the
global expression pro¢les of more than 5000 human genes
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in Et 743- and Pt 650-treated cancer cells. Our results may
provide potential clinical response markers for pharmaco-
dynamic drug assessment on the basis of gene expression
changes in tumors.
The remarkable similarities between Et 743 and Pt 650
with regard to (i) the pro¢le of antiproliferative activity
with many cell lines, (ii) the pro¢le of gene expression
changes and (iii) the e¡ect on cell cycle progression would
appear to imply that any biochemical e¡ect produced by
one of these agents but not the other may not represent
the principal or biologically most profound mode of ac-
tion of this class. The microarray data reported here are
especially compelling.
4. Materials and methods
4.1. Drugs and cell culture
Et 743 and Pt 650 (Fig. 1) were synthesized as described [6,7].
Camptothecin, adriamycin, MMC and taxol were purchased from
Calbiochem, and CDDP was from Sigma. All compounds were
dissolved in dimethyl sulfoxide (DMSO) and added to cells with
less than 1% DMSO in the ¢nal drug dilution with a culture
medium. Nine colorectal (HCT116, HCT15, SW480, SW620,
COLO320DM, COLO205, DLD-1, WiDr and HT-29), nine
lung (PC-1, PC-9, PC-10, PC-14, A-427, NCI-H460, NCI-H520,
NCI-H596 and Lu99), six gastric (MKN1, MKN7, MKN28,
MKN45, MKN74 and KATO III), six pancreatic (MIAPaCa2,
PANC-1, AsPC-1, KP-1, KP-4 and SUIT-2) and six breast
(BSY-1, HBC-5, MDA-MB-231, MDA-MB-435, MDA-MB-453
and MDA-MB-468) cancer cell lines were all cultured in
RPMI1640 (Sigma) containing 10% heat-inactivated fetal bovine
serum (Life Technologies), penicillin (100 U/ml) and streptomycin
(100 Wg/ml). The cells were maintained at 37‡C in a humidi¢ed
atmosphere of 95% air and 5% CO2.
4.2. Cell growth inhibition assay and COMPARE analysis based
on the mean graph pro¢les
Exponentially growing cells were seeded at 1.0U103^1.0U104
cells per well (100 Wl) in 96-well microtiter plates: 1.0U103 cells
for NCI-H460; 1.3U103 cells for HCT116 and DLD-1; 2.0U103
cells for COLO320DM, WiDr, PC-9, PC-14, KP-1, KP-4,
SUIT-2, MDA-MB-231, MDA-MB-435, MDA-MB-453, BSY-1
and HBC-5; 2.5U103 cells for HCT15, SW620, HT-29, PC-10,
A-427, NCI-H596, Lu99, MIAPaCa2, PANC-1, AsPC-1, MDA-
MB-468 and MKN28; 5.0U103 cells for SW480, COLO205,
NCI-H520, MKN1, MKN7, MKN45, MKN74 and KATO III;
and 1.0U104 cells for PC-1. After pre-culture for 1 day, serially
increasing concentrations of test drugs in the medium were added
to the plates. Following additional 3-day incubation, the antipro-
liferative activity was measured by the MTT colorimetric assay
[20], giving the drug concentrations required for 50% growth in-
hibition (IC50 values). The activity patterns of the compounds
were further compared according to the NCI cancer screening
method COMPARE program [21]. Based on their mean-graph
pro¢les, correlation coe⁄cients between Et 743 and other drugs
were calculated using a statistical program.
4.3. Monitoring the time-course of antiproliferative activity
HCT116 cells were seeded at 4.0U105 cells per well (2.0 ml) in
six-well plates and pre-cultured for 1 day. Et 743 and Pt 650 were
each added to the plates at the ¢nal concentration of 2.0 nM, and
then incubation was continued for 12, 24 or 48 h. At these time
points, the number of viable cells was assessed by counting the
cells with a Coulter Counter instrument.
4.4. Flow cytometric cell cycle analysis
HCT116 cells were plated at 5.0U106 cells in 10-cm diameter
dishes with 10 ml fresh medium and allowed to adhere for 1 day.
Et 743 and Pt 650 were each added to the dishes at the ¢nal
concentration of 2.0 nM, and then incubation was continued
for 12 or 24 h. For £ow cytometric analysis, the cells were ¢xed
in 70% ethanol, treated with RNase (1.0 mg/ml), and stained with
propidium iodide (50 Wg/ml). The DNA content was quantitated
by detecting red £uorescence with a £ow cytometer (FACSCali-
bur, Becton-Dickinson).
4.5. High-density oligonucleotide array analysis
HCT116 and MDA-MB-435 cells were plated in 10-cm diam-
eter dishes with 10 ml fresh medium at 5.0U106 and 3.0U106
cells per dish, respectively. After 24-h pre-incubation, the cells
were treated for 12 h with 2.0 nM of each of Et 743 and Pt
650 or with 0.015% DMSO (as control). The following micro-
array experiments were all carried out in duplicate. Details for
probe preparation and data analysis are available from A¡yme-
trix (Santa Clara, CA, USA). Brie£y, total RNA was extracted
with the TRIZOL reagent (Life Technologies), and further puri-
¢ed with an RNeasy column (Qiagen). Double-strand cDNA was
prepared from 10 Wg of total RNA by using the SuperScript
Choice System (Life Technologies) and T7-d(T)24 primer. The
cDNA product was puri¢ed by phenol/chloroform extraction.
In vitro transcription was performed with the RNA Transcript
Labeling Kit containing biotinylated UTP and CTP (Enzo Diag-
nostics). After puri¢cation with an RNeasy column, the cRNA
was fragmented and then hybridized onto A¡ymetrix GeneChip
HuGeneFL arrays for 16 h at 45‡C. According to the EukGE-
WS2 protocol, the arrays were washed and stained with strept-
avidin^phycoerythrin and biotinylated goat antistreptavidin on
an A¡ymetrix £uidics station. Fluorescence intensities were cap-
tured with a Hewlett Packard confocal laser scanner. All quanti-
tative data were processed using the A¡ymetrix GeneChip soft-
ware [31].
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